Premium
A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease
Author(s) -
Wong Kitty K.,
Alty Jane E.,
Goy Amanda G.,
Raghav Sanjay,
Reutens David C.,
Kempster Peter A.
Publication year - 2011
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.23687
Subject(s) - dyskinesia , levetiracetam , crossover study , parkinsonism , placebo , medicine , levodopa , parkinson's disease , randomized controlled trial , psychology , anesthesia , disease , psychiatry , epilepsy , pathology , alternative medicine
Background: This randomized double blind, placebo‐controlled crossover study investigated the antidyskinetic effects of levetiracetam in Parkinson's disease. Methods: Sixteen participants with levodopa‐induced dyskinesia were enrolled. Hourly videotaped dyskinesia assessments scored by the Goetz method and hourly Unified Parkinson's Disease Rating Scale motor subscale scoring were conducted on 1 day at the end of each treatment period. Results: Dyskinesia was slightly less on placebo ( P = .26). Patient diary records also showed less dyskinesia on placebo ( P = .10). Parkinsonism was a little worse on levetiracetam, at borderline statistical significance ( P = .05). Conclusions: Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties. © 2011 Movement Disorder Society
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom